[Ip-health] The variables in Dr. Peter Bach's Drug Abacus

Ruth Lopert ruth.lopert at gmail.com
Fri Jun 19 12:41:19 PDT 2015


Jamie
I have to disagree. Novel approaches should only be rewarded if they
deliver enhanced outcomes - as would be the case in other industries. We
should be rewarding the results, not the enterprise
RL

On Fri, Jun 19, 2015 at 3:35 PM, Jamie Love <james.love at keionline.org>
wrote:

> On Fri, Jun 19, 2015 at 3:31 PM, Ruth Lopert <ruth.lopert at gmail.com>
> wrote:
>
>> There is no inherent value in novelty. There are plenty of examples of
>> drugs with novel mechanisms of action that are no more effective and even
>> less effective than drugs in the classes that preceded them. Innovation
>> that addresses an unmet or inadequately met clinical need is of value, but
>> not novelty per se,
>>
>>
> Ruth,  ​I think there is a both a value associated with novelty, and
> risk.  Novel approaches may expand the tools available and stimulate new
> research paths.  But novel approaches are probably also more risky, and
> might benefit from higher rewards, all other things equal or relative.
>
> Jamie
>>
>
>



More information about the Ip-health mailing list